3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
View Patent ↗The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases.
1. A method of treating a skin disorder selected from a bullous skin disorder, atopic dermatitis, skin sensitization, skin rash, contact dermatitis, and allergic contact sensitization, in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile; and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile; or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein said skin disorder is a bullous skin disorder.
3. The method of claim 2 wherein said bullous skin disorder is pemphigus vulgaris (PV).
4. The method of claim 1 wherein said skin disorder is atopic dermatitis.
5. The method of claim 1 wherein said skin disorder is skin sensitization.
6. The method of claim 1 wherein said skin disorder is skin rash.
7. The method of claim 1 wherein said skin disorder is contact dermatitis.
8. The method of claim 1 wherein said skin disorder is allergic contact sensitization.
9. The method of claim 2 wherein said bullous skin disorder is bullous pemphigoid (BP).
10. The method of claim 1 , wherein said compound is 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile, or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein said compound is 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, or a pharmaceutically acceptable salt thereof.